Massimo Colombo, Natural history and pathogenesis of hepatitis C virus related hepatocellular carcinoma, Journal of Hepatology 1999; 31: Suppl. 1): 25-30.* |
F. Abbott et al., Neuropharmacology, 27(3):BP287-294 (1988). |
D. Faller et al., Proceedings of the American ABQssoc. for Cancer Research, Abstr. 2808, 37:411 (1996). |
J. Watkins et al., Research Commun. in Chem. Pathology and Pharmacology, 39(3):355-364 (1983). |
Antoni, et al., “NF-k B-Dependent and -Independent Pathways of HIV Activation in a Chronically Infected T Cell Line”, Virology, 202:684-694 (1994). |
Bohan et al., “Mutational Analysis of Sodium Butyrate Inducible Elements in the Human Immunodeficiency Virus Type 1 Long Terminal Repeat”, Virology, 172:573-583 (1989). |
Sadaie et al., “Induction of Developmentally Programmed Cell Death and Activation of HIV by Sodium Butyrate”, Virology, 202:513-518 (1994). |
Golub et al., “Induction of Dormant HIV-1 by Sodium Butyrate: Involvement of the TATA box in the Activation of the HIV-1 Promoter”, AIDS, 5(6):663-668 (1991). |
Tang et al., “Memory of Butyrate Induction by the Moloney Murine Sarcoma Virus Enhancer-Promoter Element”, Biochem and Biophys Res. Comm., 189(1):141-147 (1992). |
Yeivin et al., “Sodium Butyrate Selectively Induces Transcription of Promoters Adjacent to the MoMSV Viral Enhancer”, Gene, 116:159-164 (1992). |
Bohan et al., “Sodium Butyrate Activates Human Immunodeficiency Virus Long Terminal Repeat—Directed Expression”, Biochem and Biophys. Res. Comm., 148(3):899-905 (1987). |
Miller et al., “Antibodies to Butyrate-Inducible Antigens of Kaposi's Sarcoma-Associated Herpesvirus to Patient with HIV-1 Infection”, The New England J. of Med., 334(20):1292-1297 (1996). |
Faller et al., “Arginine Butyrate-induced Susceptibility to Ganciclovir in Epstein-Barr Virus (EBV)-Associated Lymphomas”, Proceedings of the Am. Assoc. for Cancer Res., 37:411-412 (1996). |
Faller et al., “Arginine Butyrate-Induced Susceptibility to Ganciclovir in an Epstein-Barr Virus (EBV) Associated Lymphona”, Am. Soc. of Hematology [Blood], 86(10)(1):342a (1995). |
Zhang, Z-X et al., J. General Virology, 65L37-46 (1984). |
Bouregeade, M.F. et al., Int'l J. of Cancer, 24:314-318 (1997). |
Huber et al., Cancer Research, 53:4619-4626 (1993). |
Huber et al., PNAS, 91:8302-8306 (1994). |
Vile et al., Cancer Research, 54:6228-6232 (1994). |
Caruso et al., PNAS, 90:7024-7028 (1993). |
DiMaio et al., Surgery, 116(2):205-213 (1994). |
O'Malley et al., Cancer Research, 55:1080-1085 (1995). |
Oldfield et al., Human Gene Therapy, 4:39-69 (1993). |
Pouillart et al., Int. J. Cancer, 51:596-601 (1992). |
Hurford et al., Nature Genetics, 10:430-435 (1995). |
Lokeshwar et al., Anticancer Research, 15:93-98 (1995). |
Donaldson et al., Int. J. Cancer, 57:847-855 (1994). |